Replies to post #13712 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Nothing you said (1 thru 7) is about the science.

Reason being you don't know the end results.

What you posted is about feelings.

My guess is feeling blue.

M$

[Kotato]

While I agree with basically all of your points below Medchem, I disagree with point 5) on searching for a signal to improve statistical power (data mining).

There is a good chance Ifenprodil does have an impact. My main reason's are:

1) More patients were most likely added to the non-treatment arm of the study receiving standard of care only. Patients could drop participation if they knew they were not receiving the drug being trialed. I need to double check this point because I do not remember in the news release if they stated which treatment arm the patients were added to. However, more patients in the non-treatment arm does also count as searching for a signal if they were trying to differentiate Ifenprodil's effects from standard of care.

2) You are assuming they have looked at the data and decided to add more patients to search for a signal. We don't know if this is true or not. I can see your thought process on jumping to this conclusion based on all the questionable decisions made and the quality of news releases. But as a statistician putting together interim data, I would hope they themselves understand to avoid data mining to satisfy the client.

3) This is perhaps my biggest reason on why I believe Ifenprodil can still have an impact moving into a Phase 3 study. Dosage.

Ifenprofil is known to be safe drug, but at what dose will it show an improvement in clinical symptoms? Do we declare the science a failure because we didn't give enough of the drug??? The dose makes the poison AND treatment. Did Algernon's high-treatment arm reach a blood plasma level to produce a minimum effective concentration???. We won't know until final data is revealed.

What we do know from their interim data was they saw a positive trend in the 40mg arm. It is my believe and opinion that 40mg is close, but not at the minimum effective concentration to have a noticeable effect on patients by day 15 of treatment.

If I recall correctly, the FDA provided Algernon with guidance and suggested a higher dosage arm of Ifenprodil before the study even began. If there is potentially a signal forming at 40mg, then Algernon might be able to increase to perhaps a 60mg dosage to verify clinical efficacy. The drug is safe and if there is data to support a potential higher dose, it should be investigated in my opinion.

-Ko

[NamesJeb]

I'm getting tired of hearing the same repeated negative garbage over and over so I'm going to provide some.... OTHER POSSIBLE VIEWS.

1. Why on earth would they not start new trials as they previously stated they would for 2021. Do you suggest everyone working at Algernon should just sit back doing nothing while awaiting results that are being INDEPENDENTLY REVIEWED? You later state money is being wasted by this organization yet you want them to sit around doing nothing getting paid? Contradiction.

2. Why would management not pay themselves well? Maybe you don't think they're worth their salaries, but do you know if they work 20 hours a week or 80? I venture a guess neither you nor I have any idea how hard they're working. Maybe to keep a good team on board a good salary is required?

3. Enrollment is enrollment, if there's not enough patients for your trial it is slowed down.... nothing can be done about this unless they find more hospitals that may have more patients. I hope you're only talking about delays that are Algernon's own fault here? Surely you aren't pissed off at the 5 people who died in a hospital fire slowing the growth of your bank account? Takes a special kind of....

4. I personally work for companies and do self employed work as well. Does that mean I provide garbage work for the companies?

5. Why on earth would they not provide interim data using all the patient data available. Sure the plan was only 75 patients, but if you have data for more, why not include them to provide a stronger signal? In what world does the fact that the primary endpoints weren't as strong yet some secondary endpoints showed great potential mean the science failed? Have you seen what's available on the market currently? Jokes. Literal jokes are the current treatment. If Ifenprodil saves even 10% of the people who were going to die it would be incredible and used worldwide.

6. Dilution is the name of the game in all penny stocks. If Ifenprodil is successful and the market reacts strongly, we'll still be laughing all the way to the bank.

7. I can agree a lot of the news releases are fairly fluffy, however would you prefer sitting around not having any idea what's going on? Do you ever read the msg boards or companies that play it that way? It's an absolute sh*show of speculation about what the hell is even going on. I'll take some fluff with my beef any day of the week over radio silence.